Looking at the role of cDC2s in melanoma, it was found that a high degree of cDC2 (BDCA1+) cells correlated with the number and activation state of CD4+ T cells, in turn linked to increased responsiveness to anti-PD-L1 therapy [71]. This evidence concerns the gene CD1C and melanoma.